659729-79-0

Basic information

• Product Name: 2(1H)-Quinoxalinone,3-amino-5-methoxy-(9CI)
• Synonyms: 2(1H)-Quinoxalinone,3-amino-5-methoxy-(9CI);3-AMINO-5-METHOXYQUINOXALIN-2(1H)-ONE;3-aMino-5-Methoxy-1,2-dihydroquinoxalin-2-one
• CAS NO: 659729-79-0
• Molecular Formula: C₉H₉N₃O₂
• Molecular Weight: 191.19
• Product Categories: PIPERIDINE
• Mol File: 659729-79-0.mol

Chemical Properties

• Appearance: /
• Density: 1.476g/cm³
• Refractive Index: 1.681
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2(1H)-Quinoxalinone,3-amino-5-methoxy-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Quinoxalinone,3-amino-5-methoxy-(9CI)(659729-79-0)
• EPA Substance Registry System: 2(1H)-Quinoxalinone,3-amino-5-methoxy-(9CI)(659729-79-0)

Safety Data

• Hazardous Substances Data: 659729-79-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2(1H)-Quinoxalinone,3-amino-5-methoxy-(9CI) is used as a chemical intermediate for the synthesis of new drugs or bioactive compounds. Its unique structure with an amino and methoxy group may contribute to its biological activity, making it a promising candidate for the development of pharmaceuticals with specific therapeutic effects.
Used in Medicinal Chemistry Research:
2(1H)-Quinoxalinone,3-amino-5-methoxy-(9CI) is used as a research compound in medicinal chemistry to explore its potential pharmacological properties and applications. Further studies are required to understand its interactions with biological targets, pharmacokinetics, and safety profile, which can help in the design and development of novel therapeutic agents.

InChI:InChI=1/C9H9N3O2/c1-14-6-4-2-3-5-7(6)12-8(10)9(13)11-5/h2-4H,1H3,(H2,10,12)(H,11,13)

Upstream product

• 83009-35-2 ethoxy-imino-acetic acid ethyl ester 
• 816-27-3 ethyl 2-ethoxy-2-iminoacetate 

Downstream Products

• 659729-85-8 3-amino-5-hydroxy-1H-quinoxalin-2-one 

Relevant articles and documents

Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate

A series of novel 4-oxopyrimidine TRPV1 antagonists was evaluated in assays measuring the blockade of capsaicin or acid-induced influx of calcium into CHO cells expressing TRPV1. The investigation of the structure-activity relationships in the heterocyclic A-region revealed the optimum pharmacophoric elements required for activity in this series and resulted in the identification of subnanomolar TRPV1 antagonists. The most potent of these antagonists were thoroughly profiled in pharmacokinetic assays. Optimization of the heterocyclic A-region led to the design and synthesis of 23, a compound that potently blocked multiple modes of TRPV1 activation. Compound 23 was shown to be effective in a rodent "on-target" biochemical challenge model (capsaicin-induced flinch, ED50 = 0.33 mg/kg p.o.) and was antihyperalgesic in a model of inflammatory pain (CFA-induced thermal hyperalgesia, MED = 0.83 mg/kg, p.o.). Based on its in vivo efficacy and pharmacokinetic profile, compound 23 (N-{4-[6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yloxy]-benzothiazol-2-yl} -acetamide; AMG 517) was selected for further evaluation in human clinical trials.

VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS

Pyrimidine ethers and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

Vanilloid receptor ligands and their use in treatments

Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache,